- Home
- VGI vs RPTX Comparison
VGI vs RPTX Comparison
Compare VGI & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | RPTX |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 92.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VGI | RPTX |
|---|---|---|
| Price | $7.80 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 46.0K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,122.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.68 | $0.89 |
| 52 Week High | $7.99 | $2.66 |
Technical Indicators
Market Signals| Indicator | VGI | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.25 | 74.94 |
| Support Level | $7.73 | $2.15 |
| Resistance Level | $7.86 | $2.66 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 86.67 | 83.96 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.